Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,626
  • Shares Outstanding, K 119,616
  • Annual Sales, $ 0 K
  • Annual Income, $ -198,640 K
  • EBIT $ -234 M
  • EBITDA $ -233 M
  • 60-Month Beta 0.64
  • Price/Sales 5.59
  • Price/Cash Flow N/A
  • Price/Book 0.69
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.96
  • Most Recent Earnings $-0.51 on 11/14/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 648.20% ( -70.78%)
  • Historical Volatility 121.68%
  • IV Percentile 95%
  • IV Rank 73.13%
  • IV High 877.55% on 11/18/24
  • IV Low 24.16% on 05/13/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 94
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 1,814
  • Open Int (30-Day) 1,849

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.33
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.42
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +50.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4043 +37.77%
on 12/20/24
0.6667 -16.45%
on 12/05/24
-0.0844 (-13.16%)
since 12/03/24
3-Month
0.4043 +37.77%
on 12/20/24
1.0700 -47.94%
on 11/07/24
-0.4036 (-42.02%)
since 10/03/24
52-Week
0.4043 +37.77%
on 12/20/24
5.1950 -89.28%
on 01/31/24
-3.2030 (-85.19%)
since 01/03/24

Most Recent Stories

More News
Insider Sale: Director at $IVVD (IVVD) Sells 125,000 Shares

TERRANCE MCGUIRE, a director at $IVVD ($IVVD), sold 125,000 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.0% of their shares....

IVVD : 0.5570 (+16.04%)
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

IVVD : 0.5570 (+16.04%)
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDAâ„¢ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

IVVD : 0.5570 (+16.04%)
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were...

IVVD : 0.5570 (+16.04%)
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

IVVD : 0.5570 (+16.04%)
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

IVVD : 0.5570 (+16.04%)
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

IVVD : 0.5570 (+16.04%)
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDAâ„¢ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

IVVD : 0.5570 (+16.04%)
Invivyd to Present PEMGARDAâ„¢ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

IVVD : 0.5570 (+16.04%)
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?

The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.

IVVD : 0.5570 (+16.04%)
PFE : 26.59 (-0.08%)

Business Summary

INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 0.6647
2nd Resistance Point 0.6123
1st Resistance Point 0.5847
Last Price 0.5570
1st Support Level 0.5047
2nd Support Level 0.4523
3rd Support Level 0.4247

See More

52-Week High 5.1950
Fibonacci 61.8% 3.3650
Fibonacci 50% 2.7997
Fibonacci 38.2% 2.2343
Last Price 0.5570
52-Week Low 0.4043

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar